Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Short term Debt (2019 - 2025)

Historic Short term Debt for Vivos Therapeutics (VVOS) over the last 4 years, with Q3 2025 value amounting to $339000.0.

  • Vivos Therapeutics' Short term Debt changed N/A to $339000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $339000.0, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2021, which is 4590.54% up from last year.
  • Per Vivos Therapeutics' latest filing, its Short term Debt stood at $339000.0 for Q3 2025.
  • In the past 5 years, Vivos Therapeutics' Short term Debt ranged from a high of $1.3 million in Q2 2021 and a low of $157000.0 during Q2 2025